JP2018531929A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531929A5
JP2018531929A5 JP2018515468A JP2018515468A JP2018531929A5 JP 2018531929 A5 JP2018531929 A5 JP 2018531929A5 JP 2018515468 A JP2018515468 A JP 2018515468A JP 2018515468 A JP2018515468 A JP 2018515468A JP 2018531929 A5 JP2018531929 A5 JP 2018531929A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
subject
liver disease
neuronal loss
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018515468A
Other languages
English (en)
Japanese (ja)
Other versions
JP6989495B2 (ja
JP2018531929A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/053176 external-priority patent/WO2017053613A1/en
Publication of JP2018531929A publication Critical patent/JP2018531929A/ja
Publication of JP2018531929A5 publication Critical patent/JP2018531929A5/ja
Application granted granted Critical
Publication of JP6989495B2 publication Critical patent/JP6989495B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018515468A 2015-09-25 2016-09-22 Ｌ−オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる神経細胞喪失の治療および予防 Active JP6989495B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562233002P 2015-09-25 2015-09-25
US62/233,002 2015-09-25
PCT/US2016/053176 WO2017053613A1 (en) 2015-09-25 2016-09-22 Treatment and prevention of neuronal cell loss using l-ornithine in combination with at least one of phenylacetate and phenylbutyrate

Publications (3)

Publication Number Publication Date
JP2018531929A JP2018531929A (ja) 2018-11-01
JP2018531929A5 true JP2018531929A5 (enExample) 2019-11-07
JP6989495B2 JP6989495B2 (ja) 2022-01-05

Family

ID=58387333

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018515468A Active JP6989495B2 (ja) 2015-09-25 2016-09-22 Ｌ−オルニチンをフェニルアセテートおよびフェニルブチレートのうちの少なくとも１つと組み合わせて用いる神経細胞喪失の治療および予防

Country Status (7)

Country Link
US (1) US20200206174A1 (enExample)
EP (1) EP3352748A4 (enExample)
JP (1) JP6989495B2 (enExample)
AU (1) AU2016325556B2 (enExample)
CA (1) CA2998490A1 (enExample)
HK (1) HK1257679A1 (enExample)
WO (1) WO2017053613A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2652187T3 (es) 2009-04-03 2018-01-31 Ocera Therapeutics, Inc. Fenilacetato de l-ornitina y métodos para elaborar el mismo
EP2440200B8 (en) 2009-06-08 2014-10-15 UCL Business PLC Treatment of portal hypertension using l-ornithine phenylacetate
KR102487376B1 (ko) 2014-11-24 2023-01-10 유씨엘 비즈니스 리미티드 암모니아-저감 치료를 이용한 간성상세포 활성화와 연관된 질병의 치료
SG11201802987UA (en) * 2015-11-13 2018-05-30 Ocera Therapeutics Inc Formulation of l-ornithine phenylacetate
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
SG11202001142VA (en) 2017-08-14 2020-03-30 Axcella Health Inc Amino acid compositions for the treatment of liver disease
WO2019226786A1 (en) * 2018-05-22 2019-11-28 Duke University Compositions and methods for treating neurodegenerative disorders with rifaximin
US10596136B2 (en) 2018-06-20 2020-03-24 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
AU2020270106A1 (en) * 2019-05-09 2021-11-18 Ocera Therapeutics, Inc. Methods of assessing and treating hepatic encephalopathy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4783443A (en) 1986-03-03 1988-11-08 The University Of Chicago Amino acyl cephalosporin derivatives
CN1304723A (zh) * 2001-01-16 2001-07-25 中山大学 含二氢呋喃环结构的丹参酮类化合物用于治疗肝性脑病的药物
ES2448549T3 (es) 2004-11-26 2014-03-14 Ucl Business Plc Composiciones que comprenden ornitina y fenilacetato o fenilbutirato para tratar encefalopatía hepática
ES2652187T3 (es) * 2009-04-03 2018-01-31 Ocera Therapeutics, Inc. Fenilacetato de l-ornitina y métodos para elaborar el mismo
EP2440200B8 (en) * 2009-06-08 2014-10-15 UCL Business PLC Treatment of portal hypertension using l-ornithine phenylacetate

Similar Documents

Publication Publication Date Title
JP2008521784A5 (enExample)
JP2014532654A5 (enExample)
JP2014139255A5 (enExample)
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
HRP20250615T1 (hr) Tradipitant za upotrebu u liječenju gastropareze
HRP20210294T1 (hr) Postupci liječenja akutnog bubrežnog oštećenja
JP2016535780A5 (enExample)
JP2012524770A5 (enExample)
JP2017514911A5 (enExample)
JP2017105861A5 (enExample)
JP2008545703A5 (enExample)
ES2361915T3 (es) Utilización de la betaína para el tratamiento de la claudicación intermitente.
Liu et al. Urolithin A alleviates early brain injury after subarachnoid hemorrhage by regulating the AMPK/mTOR pathway-mediated autophagy
JP2019529569A5 (enExample)
Yilmaz et al. Cytidine 5′‐diphosphocholine restores blood flow of superior mesenteric and renal arteries and prolongs survival time in haemorrhaged anaesthetized rats
CN107648213A (zh) 恩利卡生在制备治疗缺血/再灌注损伤药物中的应用
ES2965493T3 (es) Compuesto y composición para su uso en el tratamiento preventivo y/o curativo de enfermedades del sistema nervioso central caracterizadas por una disminución de la plasticidad neuronal, en concreto caracterizadas por una disminución de la plasticidad sináptica
El Gharabawy et al. Histological effects of sofosbuvir on the kidney of male albino rats and the possible protective role of vitamin C
CN101991573A (zh) 去氢钩藤碱及其异构体在制备药物中的用途
JP6100510B2 (ja) 抗感冒剤
JP7699855B2 (ja) シロスタゾールを含む組成物の脳血管疾患の治療薬の調製への応用
JP7778396B2 (ja) シロスタゾールを含む組成物の脳血管疾患への応用
JP2022543598A5 (enExample)
CN103800318B (zh) 巴西苏木素在制备用于防治肝肾损伤的药物中的应用
Borsky et al. Comparative Evaluation of Urolithin A and Spermidine: A Duel for Autophagic and Mitophagic Dominance in Dietary Supplements